Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL3818 in Recurrent or Metastatic Gynecologic Cancers
NCT02584478Phase 3Active, not recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Dec 2015
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of anlotinib in endometrial carcinoma, ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), cervical carcinoma, sponsored by Advenchen Laboratories. Started Dec 2015; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
endometrial carcinomaovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)cervical carcinoma
Beyond the preview
Go deeper on NCT02584478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584478.